These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 12579770)

  • 21. Kinases as targets in the treatment of solid tumors.
    Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
    Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making real progress against breast cancer. Some of the best cancer news this year has been the success of targeted approaches to treating breast cancer.
    Harv Womens Health Watch; 2005 Oct; 13(2):1-3. PubMed ID: 16320417
    [No Abstract]   [Full Text] [Related]  

  • 24. Emerging targeted therapies for breast cancer.
    Johnson ML; Seidman AD
    Oncology (Williston Park); 2005 Apr; 19(5):611-8. PubMed ID: 15945342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.
    Mano MS; Awada A; Minisini A; Durbecq V; Di Leo A; Piccart M
    Breast; 2004 Aug; 13(4):347-9. PubMed ID: 15325672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant trastuzumab for breast cancer.
    Dent R; Clemons M
    BMJ; 2005 Nov; 331(7524):1035-6. PubMed ID: 16269471
    [No Abstract]   [Full Text] [Related]  

  • 27. Lapatinib: current status and future directions in breast cancer.
    Moy B; Goss PE
    Oncologist; 2006; 11(10):1047-57. PubMed ID: 17110623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer drug offers dramatic results for some.
    Mayo Clin Health Lett; 2006 Mar; 24(3):4. PubMed ID: 16566074
    [No Abstract]   [Full Text] [Related]  

  • 29. New breast cancer drug.
    Harv Womens Health Watch; 1998 Nov; 6(3):7. PubMed ID: 9814134
    [No Abstract]   [Full Text] [Related]  

  • 30. Neutrophil elastase predicts trastuzumab responsiveness in metastatic breast cancer.
    Yamashita J; Akizuki M; Jotsuka T; Harao M; Nakano S
    Breast J; 2006; 12(3):288. PubMed ID: 16684339
    [No Abstract]   [Full Text] [Related]  

  • 31. Herceptin.
    Peyrot J
    Oncol Nurs Forum; 1999 Apr; 26(3):515-6. PubMed ID: 10214591
    [No Abstract]   [Full Text] [Related]  

  • 32. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 33. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.
    Kurosumi M
    Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922
    [No Abstract]   [Full Text] [Related]  

  • 34. Targeting progress: the development of growth factor receptor-directed therapy.
    Hortobagyi GN; Khayat D
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):1-2. PubMed ID: 11049050
    [No Abstract]   [Full Text] [Related]  

  • 35. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy.
    Mendelsohn J; Dinney CP
    J Urol; 2001 Apr; 165(4):1152-7. PubMed ID: 11257658
    [No Abstract]   [Full Text] [Related]  

  • 36. Opportunities and challenges in the development of targeted therapies.
    Hortobagyi GN
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):21-7. PubMed ID: 15052540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors.
    Lin NU; Winer EP
    Breast Cancer Res; 2004; 6(5):204-10. PubMed ID: 15318926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".
    Hughes A; Clarson J; Gargett T; Yu W; Brown MP; Lopez AF; Hughes TP; Yong AS
    Leuk Res; 2017 Apr; 55():55-57. PubMed ID: 28129558
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic targeting of signal transduction pathways and proteins in breast cancer.
    Hynes NE; Gullick W
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):1-2. PubMed ID: 16865535
    [No Abstract]   [Full Text] [Related]  

  • 40. "HIT"ing back against NETs.
    Swaidani S; McCrae KR
    Blood; 2020 Mar; 135(10):706-707. PubMed ID: 32135015
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.